Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with many patients failing to achieve adequate symptom control despite multiple available antidepressants. Positive topline results from Definium Therapeutics' Phase 3 …

The biotech industry in 2024 has seen several high-profile patent disputes that have shaped the landscape of innovation and legal precedent. These cases have centered around cutting-edge technologies such as CRISPR gene editing, mRNA …

With a focus on addressing a wide spectrum of diseases and conditions, the US witnessed the most novel drug approvals in 6 years. Here we provide an overview of the key highlights in treatments …

In 2019, Novartis’s gene therapy Zolgensma made news as the „most expensive single-dose drug ever“ with $2.125 million. Just 3 years later, as of November 2022, bluebird bio’s Skysona, with the price tag of …